|
Enterprises active in the field of biotechnology
|
|
| 2011-2016 | NTS-2 | 4 |
Enterprise operating in the field of biotechnology (biotechnology firm) - an enterprise that uses one or more techniques of biotechnology (as defined biotechnology) for the production of goods or services and / or to carry out systematic research and development (R & D) in order to increase the resources knowledge and its economic applications.
|
|
Enterprises by major business in biotechnology
|
|
| 2011-2016 | NTS-2 | 24 |
The areas of activity in the field of biotechnology:
- Human health (with and without rDNA technology)
- Human health (with rDNA technology) large molecule therapeutics and monoclonal antibodies produced using rDNA technology,
- Human health (without rDNA technology) other therapeutics, artificial substrates, diagnostics and drug delivery technologies, etc.,
- Veterinary health diagnostics, vaccination and medical treatment of animals,
- GM agriculture new varieties of genetically modified (GM) plants, animals and micro-organisms,
- Non-GM agriculture new varieties of non-GM plants, animals and micro-organisms developed using biotechnology techniques, bio-pest controls, etc.,
- Natural resources mining, petroleum/energy extraction , etc.,
- Environment diagnostics, bioremediation, waste disposal, clean production, etc.,
- Industrial processing food, cosmetics, fuels, chemicals (e.g. enzymes), plastics, etc.,
- Bioinformatics- creating genomic/protein databases, modeling biotechnological complex processes, systems biology,
- Non-specific applications research tools,
- Other.
The main (dominant) area of operations in the field of biotechnology: indicated by an area of application of biotechnology techniques, which incurred the greatest costs or generating the most revenue from the sale of biotechnology products.
|
|
Internal current expenditure on research and development (R & D) in the field of biotechnology by type of expenditure in scientific units
|
|
| 2011-2016 | NTS-2 | 4 |
Current expenditures on R&D - personnel costs as well as costs of used materials, non-durable articles and energy, costs of external services (other than R&D) including external processing, transport, renovation, banking, postal, ICT, publishing or municipal services, costs of business trips and other current costs including, in particular, taxes and fees encumbering costs of activity and profits, property insurance, and equivalents for the benefit of employees in a part in which they relate to R&D. Depreciation of fixed assets and VAT are excluded.
|
|
Internal expenditure on biotechnology in enterprises by financing sources
|
|
| 2011-2016 | NTS-2 | 6 |
Business enterprises funds: funds received from business enterprises. Budgetary funds: R&D received funds from the budget (Ministry of Science and Higher Education and other ministries and local government units). Abroad funds: R&D received funds from the European Union, international organisations and foreign institutions.
|